Japans National Hospital Director Reprimanded For Accepting High Fees For Speeches From Pharma Companies
This article was originally published in PharmAsia News
Executive Summary
Japans National Cardiovascular Center Director Masafumi Kitakaze got his salary reduced for six months for accepting high fees from pharmaceutical companies for speeches. According to the Osaka-based national hospital, Kitakase spoke at 55 events sponsored by pharmac companies from October to December 2006, and received 9.3 million in compensation. The compensation standard, which is 60,000 per hour, is three times higher than the allowed 20,000 or less per hour set by the Ministry of Health, Labor and Welfare. The center also disclosed that Kitakaze falsified the speech time and reported only 7.2 million in compensation.( href='http://www.jiji.com/jc/c?g=soc&k=2009033101128'>Click here for more Japanese language) "National Cardiovascular Center Director Punished For Falsified Report, Receives 9.3 Million In Speech Fees In Three Month" - Jiji Press News (3/31/09)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.